Belgium· BE-AMP-SAM516400-00
Mavenclad 10 mg
A cladribine product containing cladribine, registered in Belgium by Merck Europe. The same ATC class is registered in 12 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Cladribine is registered in 12 of 19 countries.
Countries holding a registration under ATC L04AA40 (cladribine), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 8 of them publish a price we can compare per daily dose
Cladribine · ATC L04AA40
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of cladribine costs, country by country.
Normalised to the WHO defined daily dose (0.34 mg), the median price runs from $0.048 in France to $90.83 in Switzerland — a ×1908 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Cladribine · price per daily dose (0.34 mg)
USD · FX 28 Sept 2026
- CH Switzerland$90.83
- FR France$0.048
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Cladribine
- Manufacturer
- Merck Europe
- Country
- Belgium (BE)
- ATC code
- L04AA40
- ATC class
- Cladribine
- Defined daily dose
- 0.34 mg, O
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 5
- be_apb3678091
- be_apb7722937
- be_apb3677804
- be_apb3677812
- be_apb4200481
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
409 interactions on record for cladribine.
Graded by severity as the source publishes them — 326 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Cladribine · interactions on record
409 records
- 326 severe
- 79 moderate
- 4 info
Most severe, free to view
- PrednisoloneA07EA01severe
- HydrocortisoneA07EA02severe
- PrednisoneA07EA03severe
- BetamethasoneA07EA04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Cladribine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaLEUJECTAtnahs Pharma Netherlands B.V., Amsterdam
- United StatesCladribineHisun Pharmaceuticals USA, Inc.
- FinlandLeujectAtnahs Pharma Netherlands B.V.
- SwitzerlandLitak 10, Injektions- / InfusionslösungLipomed AG
- SpainLEUSTATIN 1 MG/ML SOLUCION PARA PERFUSIONAtnahs Pharma Netherlands Bv.
- NetherlandsLeustatin 2 mg/ml oplossing voor injectieAtnahs Pharma Netherlands B.V.
- PolandBiodribinSieć Badawcza Łukasiewicz – Instytut Chemii Przemysłowej im. Prof. I. Mościckiego
- United KingdomLeustat 10mg/10ml solution for infusion vialsAtnahs Pharma UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 22 EEA countries. Names it is sold under:
- Austria · Leuject
- Bulgaria · Леуджект
- Czechia · Leuject
- Germany · Leustatin
- Spain · Leustatin
- Finland · Leuject
- France · Leustatine
- United Kingdom (Northern Ireland) · Cladribine Zentiva, Leustat
- Greece · Leustatin
- Croatia · Leuject
- Hungary · Leuject
- Iceland · Mavenclad
- Italy · Leustatin
- Liechtenstein · Mavenclad
- Luxembourg · Leustatin
- Netherlands · Leustatin
- Norway · Leuject, Mavenclad
- Poland · Biodribin, Leuject
- Portugal · Cladribina Generis, Leustatin
- Romania · Leuject
- Sweden · Leuject
- Slovenia · Leuject
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b59baac7-225f-4ad1-a9b5-9b8226bb759b GET /v1/drugs/b59baac7-225f-4ad1-a9b5-9b8226bb759b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablet",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Mavenclad 10 mg",
"name_fr": "Mavenclad 10 mg",
"name_nl": "Mavenclad 10 mg",
"amp_code": "SAM516400-00",
"strengths": [
"10.0000",
"64.0000"
],
"pack_count": 10,
"substances": [
"Cladribine",
"Hydroxypropylbetadex",
"Sorbitol"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Cladribine",
"authorisation_numbers": [
"EU/1/17/1212/002",
"EU/1/17/1212/001",
"EU/1/17/1212/004",
"EU/1/17/1212/003",
"EU/1/17/1212/006",
"EU/1/17/1212/005"
]
}See everything about cladribine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.